Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Relmada Therapeutics, Inc. (OTC: RLMD).

Full DD Report for RLMD

You must become a subscriber to view this report.


Recent News from (OTC: RLMD)

Relmada Therapeutics Allowed Patent Application in China Covering NMDA Receptor Antagonist d-Methadone for Treatment of Psychiatric Symptoms
NEW YORK , Aug. 9, 2018 /PRNewswire/ -- Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, today announced that the State Intellectual Property Office of China has issued a Decision to...
Source: PR Newswire
Date: August, 09 2018 08:00
Relmada Therapeutics Inc. Announces First Patient Dosed in Phase 2 Study of REL-1017 in Patients with Major Depressive Disorder
NEW YORK , June 27, 2018 /PRNewswire/ -- Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, today announced the dosing of the first patient in the Company's Phase 2 clinical study t...
Source: PR Newswire
Date: June, 27 2018 08:00
Dr. Ottavio Vitolo Joins Relmada Therapeutics as Senior Vice President, Head of R&D and Chief Medical Officer
NEW YORK , April 3, 2018 /PRNewswire/ -- Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, today announced that Dr. Ottavio Vitolo has joined the company as senior vice president...
Source: PR Newswire
Date: April, 03 2018 08:00
Relmada nabs expanded rights to CNS candidate dextromethadone; shares ahead 8%
Relmada Therapeutics ( OTCQB:RLMD +8.3% ) has acquired global rights to develop and commercialize lead candidate dextromethadone (REL-1017) for the treatment of neurological conditions, including certain rare diseases, that affect the central nervous system (CNS). It previously owned the...
Source: SeekingAlpha
Date: January, 17 2018 11:35
Relmada Therapeutics Acquires Global Rights to Develop and Market Dextromethadone for Treatment of Disorders of the Nervous System
NEW YORK , Jan. 17, 2018 /PRNewswire/ -- Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, announced today that it has acquired the global rights to develop and market dextromethadone (...
Source: PR Newswire
Date: January, 17 2018 08:00
Relmada Therapeutics Announces Notice of Acceptance of Key Patent in Europe Covering NMDA Receptor Antagonist d-Methadone for Treatment of Psychiatric Symptoms
NEW YORK , Jan. 9, 2018 /PRNewswire/ -- Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, announced today that the European Patent Office has issued a notice of allowance for paten...
Source: PR Newswire
Date: January, 09 2018 08:00
Relmada Therapeutics Announces Notice of Acceptance of Key Patent in Australia Covering NMDA Receptor Antagonist d-Methadone for Treatment of Psychiatric Symptoms
NEW YORK , Oct. 27, 2017 /PRNewswire/ -- Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, announced today that IP Australia has issued a notice of acceptance for patent applicatio...
Source: PR Newswire
Date: October, 27 2017 08:00
NetworkNewsBreaks - Top 10 Mid-day Percentage Gainers on October 5, 2017
Here is a list of stocks shaking up the markets today, with particular focus on NASDAQ and OTC small caps. The top gainers based on percentage: LPAD 32.73% – News: Enters definitive merger agreement for Icynene to acquire all outstanding shares USEG 26.92% – News: Enters agre...
Source: NetworkNewsWire
Date: October, 05 2017 13:00
Relmada secures $6.9M private capital raise; shares up 6%
Relmada Therapeutics ( OTCQB:RLMD +5.6% ) inks an agreement for the direct sale of convertible promissory notes and warrants that will yield gross proceeds of ~$6.9M. More news on: Relmada Therapeutics, Inc., Healthcare stocks news, Stocks on the move, Read more ...
Source: SeekingAlpha
Date: October, 05 2017 09:57
Relmada Therapeutics Announces $6.9 Million Private Placement
NEW YORK , Oct. 5, 2017 /PRNewswire/ -- Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, today announced a private placement of convertible promissory notes and warrants to n...
Source: PR Newswire
Date: October, 05 2017 08:00

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-141.161.161.161.1612,000
2018-12-131.201.151.201.157,668
2018-12-121.151.101.151.1016,405
2018-12-111.201.231.231.1514,785
2018-12-101.181.151.181.1510,400

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-147,00012,00058.3333Short
2018-12-132,0007,66826.0824Cover
2018-12-128,68416,40552.9351Short
2018-12-115,94714,78540.2232Short
2018-12-106,35310,40061.0865Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on RLMD.


About Relmada Therapeutics, Inc. (OTC: RLMD)

Logo for Relmada Therapeutics, Inc. (OTC: RLMD)

Relmada Therapeutics is a clinical stage, publicly traded biotechnology company developing novel versions of proven drug products together with new chemical entities that potentially address areas of high unmet medical need in the treatment of central nervous system CNS diseases. The Company has a diversified portfolio of four products at various stages of development, including d Methadone dextromethadone, REL , an N methyl D aspartate NMDA receptor antagonist for depression and neuropathic pain LevoCap ER REL , an abuse resistant, sustained release dosage form of the opioid analgesic levorphanol oral buprenorphine BuTab, REL , an oral dosage form of the opioid analgesic buprenorphine and topical mepivacaine MepiGel, REL , an orphan drug designated topical formulation of the local anesthetic mepivacaine. The Company s product development efforts are guided by the internationally recognized scientific expertise of its research team. The Company s approach is expected to reduce clinical development risks and costs while potentially delivering valuable products to address areas of high unmet medical needs.

 

 

 

Current Management

  • Sergio Traversa / CEO
  • Thomas Slusarczyk / Counsel
  • Charles Casamento /
  • Paul Kelly /
  • Maged Shenouda /
  • Sergio Traversa /

Current Share Structure

  • Market Cap: $8,782,537 - 03/15/2018
  • Authorized: 100,000,000 - 02/28/2018
  • Issue and Outstanding: 12,728,315 - 02/28/2018

 


Recent Filings from (OTC: RLMD)

Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 14 2018
Securities offered to employees under employee benefit plans
Filing Type: S-8Filing Source: edgar
Filing Date: May, 14 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 05 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 02 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: February, 12 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: February, 05 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: January, 19 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: December, 15 2017
OTCQB Certification - OTCQB Certification
Filing Type: OTCQB Certification - OTCQB CertificationFiling Source: OTC Markets
Filing Date: November, 22 2017
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: November, 14 2017

 

 


Daily Technical Chart for (OTC: RLMD)

Daily Technical Chart for (OTC: RLMD)


Stay tuned for daily updates and more on (OTC: RLMD)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: RLMD)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in RLMD is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of RLMD and does not buy, sell, or trade any shares of RLMD. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/